title: Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Saye
authors.initials: S
authors.lastname: Khoo
authors.forename: Marta
authors.initials: M
authors.lastname: Boffito
authors.forename: David
authors.initials: D
authors.lastname: Back
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D019438:Ritonavir / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D019438:Ritonavir